home / stock / huge / huge news

HUGE News and Press, FSD Pharma Inc. From 02/21/23

Stock Information
Company Name: FSD Pharma Inc.
Stock Symbol: HUGE
Market: NASDAQ
Website: fsdpharma.com
Menu
HUGE HUGE Quote HUGE Short HUGE News HUGE Articles HUGE Message Board
Get HUGE Alerts

News, Short Squeeze, Breakout and More Instantly...
HUGE - InvestorNewsBreaks - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) to Interact with Leaders Pushing Boundaries of MS Research at Upcoming Forum

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders. The company today announced upcoming participati...
HUGE - FSD Pharma Presenting Two Scientific Posters on Preclinical Toxicology and Efficacy Data of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2023 Forum

FSD Pharma releases new corporate video providing insight on the Company’s innovation to help millions of people suffering from Multiple Sclerosis Morningstar releases research coverage on HUGE, noting outperformance of peers in recent months and undervalued quantitative valuation ...

HUGE - FSD Pharma regains compliance with Nasdaq

FSD Pharma ( NASDAQ: HUGE ) has announced that the company has received confirmation from The Nasdaq that it has regained compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule. On Feb. 14, 2023, Staff notified the company that for the last ...

HUGE - FSD Pharma Regains Compliance with NASDAQ Continued Listing Requirements

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“ FSD Pharma ” or the “ Company ”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory...
HUGE - InvestorNewsBreaks - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Launches New Program Targeting Unmet Medical Needs for Alcohol Misuse

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders. The company today announced the launch of a new ...

HUGE - FSD Pharma launches research program for alcohol misuse; plans issue of warrants

FSD Pharma ( NASDAQ: HUGE ) said it launched of a new research and development program focused on alcohol misuse. "FSD Pharma’s existing pipelines and research priorities in brain and inflammatory disorders, including mental health, provides a natural extension to investigate t...

HUGE - FSD Pharma Launches A New Research and Development Program Targeting Unmet Medical Needs for Alcohol Misuse

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“ FSD Pharma ” or the “ Company ”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory...
HUGE - InvestorNewsBreaks - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Receipt of No Objection Letter from Health Canada Is Focus of Recent InvestmentPitch Media Video

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) , a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, has received a No Objection Letter from Health Can...

HUGE - InvestmentPitch Media Video Discusses FSD Pharma's Receipt of No Objection Letter from Health Canada for Clinical Trials for LUCID-21-302 for MS

VANCOUVER, British Columbia, Feb. 09, 2023 (GLOBE NEWSWIRE) -- FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FSE:0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabol...

HUGE - FSD Pharma gains as Canada clears early-stage study for multiple sclerosis candidate

The shares of Canadian biotech FSD Pharma ( NASDAQ: HUGE ) rose for the fourth consecutive session on Tuesday after announcing that Canada greenlighted its Phase 1 trial for multiple sclerosis candidate LUCID-21-302. Issuing a No Objection Letter (NOL), Health Canada has granted the r...
Previous 10 Next 10